Tetsuya Mitsudomi

List of Publications by Citations

323 papers	33,331 citations	77 h-index	179 g-index
339 ext. papers	37,920 ext. citations	5.6 avg, IF	6.8 L-index

#	Paper	IF	Citations
323	MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. *Science*, **2007**, 316, 1039-43	33.3	3705
322	International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. *Journal of Thoracic Oncology*, **2011**, 6, 244-85	8.9	3178
321	Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. *Lancet Oncology, The*, **2010**, 11, 121-8	21.7	3140
320	Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. *Cancer Research*, **2004**, 64, 3753-6	10.1	2077
319	Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. *Cancer Research*, **2004**, 64, 8919-23	10.1	1059
318	EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. *New England Journal of Medicine*, **2010**, 363, 1734-9	59.2	940
317	Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. *Journal of Clinical Oncology*, **2005**, 23, 2513-20	2.2	839
316	Reduced expression of Dicer associated with poor prognosis in lung cancer patients. *Cancer Science*, **2005**, 96, 111-5	6.9	529
315	Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial. *Lancet, The*, **2017**, 390, 29-39	40	528
314	Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. *Clinical Cancer Research*, **2006**, 12, 5764-9	12.9	526
313	Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. *Cancer Research*, **2008**, 68, 9479-87	10.1	522
312	Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. *Cancer Science*, **2007**, 98, 1817-24	6.9	469
311	Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study. *Lancet Oncology, The*, **2016**, 17, 1643-1652	21.7	412
310	Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer. *FEBS Journal*, **2010**, 277, 301-8	5.7	355
309	A prospective radiological study of thin-section computed tomography to predict pathological noninvasiveness in peripheral clinical IA lung cancer (Japan Clinical Oncology Group 0201). *Journal of Thoracic Oncology*, **2011**, 6, 751-6	8.9	344
308	TTF-1 expression in pulmonary adenocarcinomas. *American Journal of Surgical Pathology*, **2002**, 26, 767-73	6.7	307
307	Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Oncology, The*, **2016**, 17, 822-835	21.7	289

306	Expression profile-defined classification of lung adenocarcinoma shows close relationship with underlying major genetic changes and clinicopathologic behaviors. *Journal of Clinical Oncology*, **2006**, 24, 1679-88	2.2	257
305	Genome-wide association analysis identifies new lung cancer susceptibility loci in never-smoking women in Asia. *Nature Genetics*, **2012**, 44, 1330-5	36.3	237
304	Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers. *Journal of Thoracic Oncology*, **2009**, 4, 5-11	8.9	230
303	Impact of Specific Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy in EGFR-Mutant Lung Cancer: A Meta-Analysis. *Journal of Clinical Oncology*, **2015**, 33, 1958-65	2.2	211
302	Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib. *Journal of Thoracic Oncology*, **2011**, 6, 1152-61	8.9	211
301	Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy. *Cancer Science*, **2016**, 107, 1179-86	6.9	210
300	EGFR mutation is specific for terminal respiratory unit type adenocarcinoma. *American Journal of Surgical Pathology*, **2005**, 29, 633-9	6.7	206
299	Radiographically determined noninvasive adenocarcinoma of the lung: survival outcomes of Japan Clinical Oncology Group 0201. *Journal of Thoracic and Cardiovascular Surgery*, **2013**, 146, 24-30	1.5	197
298	Heterogeneous distribution of EGFR mutations is extremely rare in lung adenocarcinoma. *Journal of Clinical Oncology*, **2011**, 29, 2972-7	2.2	185
297	Prognostic implication of EGFR, KRAS, and TP53 gene mutations in a large cohort of Japanese patients with surgically treated lung adenocarcinoma. *Journal of Thoracic Oncology*, **2009**, 4, 22-9	8.9	185
296	Plasma ctDNA Analysis for Detection of the EGFR T790M Mutation in Patients with Advanced Non-Small Cell Lung Cancer. *Journal of Thoracic Oncology*, **2017**, 12, 1061-1070	8.9	178
295	Reduced expression of class II histone deacetylase genes is associated with poor prognosis in lung cancer patients. *International Journal of Cancer*, **2004**, 112, 26-32	7.5	177
294	Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort. *Journal of Thoracic Oncology*, **2011**, 6, 2011-7	8.9	176
293	Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancer. *Clinical Cancer Research*, **2010**, 16, 5489-98	12.9	175
292	Mutations of the p53 gene as a predictor of poor prognosis in patients with non-small-cell lung cancer. *Journal of the National Cancer Institute*, **1993**, 85, 2018-23	9.7	173
291	Impact and predictors of acute exacerbation of interstitial lung diseases after pulmonary resection for lung cancer. *Journal of Thoracic and Cardiovascular Surgery*, **2014**, 147, 1604-1611.e3	1.5	171
290	Predictors of survival in patients with bone metastasis of lung cancer. *Clinical Orthopaedics and Related Research*, **2008**, 466, 729-36	2.2	169
289	Biological and clinical implications of EGFR mutations in lung cancer. *International Journal of Clinical Oncology*, **2006**, 11, 190-8	4.2	169

288	Lineage-specific dependency of lung adenocarcinomas on the lung development regulator TTF-1. *Cancer Research*, **2007**, 67, 6007-11	10.1	168
287	Comparison of pulmonary segmentectomy and lobectomy: Safety results of a randomized trial. *Journal of Thoracic and Cardiovascular Surgery*, **2019**, 158, 895-907	1.5	167
286	Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation. *Cancer and Metastasis Reviews*, **2010**, 29, 49-60	9.6	164
285	A rapid, sensitive assay to detect EGFR mutation in small biopsy specimens from lung cancer. *Journal of Molecular Diagnostics*, **2006**, 8, 335-41	5.1	162
284	Combined survival analysis of prospective clinical trials of gefitinib for non-small cell lung cancer with EGFR mutations. *Clinical Cancer Research*, **2009**, 15, 4493-8	12.9	159
283	Relapse-related molecular signature in lung adenocarcinomas identifies patients with dismal prognosis. *Journal of Clinical Oncology*, **2009**, 27, 2793-9	2.2	153
282	The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation-Positive Non-Small Cell Lung Cancer: Status in 2016. *Journal of Thoracic Oncology*, **2016**, 11, 946-63	8.9	145
281	Prognostic value of c-erbB-2 protein expression in human lung adenocarcinoma and squamous cell carcinoma. *European Journal of Cancer & Clinical Oncology*, **1991**, 27, 1372-5		142
280	Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival. *Journal of the National Cancer Institute*, **2017**, 109,	9.7	136
279	Prognostic model of pulmonary adenocarcinoma by expression profiling of eight genes as determined by quantitative real-time reverse transcriptase polymerase chain reaction. *Journal of Clinical Oncology*, **2004**, 22, 811-9	2.2	136
278	Phase II trial of preoperative chemoradiotherapy followed by surgical resection in patients with superior sulcus non-small-cell lung cancers: report of Japan Clinical Oncology Group trial 9806. *Journal of Clinical Oncology*, **2008**, 26, 644-9	2.2	132
277	Efficacy of erlotinib for brain and leptomeningeal metastases in patients with lung adenocarcinoma who showed initial good response to gefitinib. *Journal of Thoracic Oncology*, **2009**, 4, 1415-9	8.9	129
276	Epidermal growth factor receptor mutations in small cell lung cancer. *Clinical Cancer Research*, **2008** , 14, 6092-6	12.9	129
275	Prospective Validation for Prediction of Gefitinib Sensitivity by Epidermal Growth Factor Receptor Gene Mutation in Patients with Non-Small Cell Lung Cancer. *Journal of Thoracic Oncology*, **2007**, 2, 22-28	8.9	129
274	EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs. *Clinical Cancer Research*, **2015**, 21, 5305-13	12.9	126
273	EGFR T790M mutation: a double role in lung cancer cell survival?. *Journal of Thoracic Oncology*, **2009**, 4, 1-4	8.9	126
272	Epidermal growth factor receptor gene amplification is acquired in association with tumor progression of EGFR-mutated lung cancer. *Cancer Research*, **2008**, 68, 2106-11	10.1	120
271	Gene expression-based, individualized outcome prediction for surgically treated lung cancer patients. *Oncogene*, **2004**, 23, 5360-70	9.2	120

270	Clinical and pathologic features of lung cancer expressing programmed cell death ligand 1 (PD-L1). *Lung Cancer*, **2016**, 98, 69-75	5.9	114
269	Gene-environment interactions between the smoking habit and polymorphisms in the DNA repair genes, APE1 Asp148Glu and XRCC1 Arg399Gln, in Japanese lung cancer risk. *Carcinogenesis*, **2004**, 25, 1395-401	4.6	112
268	Acquired resistance mechanisms to tyrosine kinase inhibitors in lung cancer with activating epidermal growth factor receptor mutation--diversity, ductility, and destiny. *Cancer and Metastasis Reviews*, **2012**, 31, 807-14	9.6	110
267	Aberrant hypermethylation of the CHFR prophase checkpoint gene in human lung cancers. *Oncogene*, **2002**, 21, 2328-33	9.2	110
266	Expression of cancer/testis (CT) antigens in lung cancer. *Lung Cancer*, **2003**, 42, 23-33	5.9	110
265	Analysis of Heritability and Shared Heritability Based on Genome-Wide Association Studies for Thirteen Cancer Types. *Journal of the National Cancer Institute*, **2015**, 107, djv279	9.7	107
264	EGFR mutation and response of lung cancer to gefitinib. *New England Journal of Medicine*, **2005**, 352, 2136; author reply 2136	59.2	106
263	Prognostic and predictive implications of HER2/ERBB2/neu gene mutations in lung cancers. *Lung Cancer*, **2011**, 74, 139-44	5.9	104
262	Epidermal growth factor receptor inhibition in lung cancer: status 2012. *Journal of Thoracic Oncology*, **2013**, 8, 373-84	8.9	99
261	Molecular diagnosis of activating EGFR mutations in non-small cell lung cancer using mutation-specific antibodies for immunohistochemical analysis. *Clinical Cancer Research*, **2010**, 16, 3163-70	12.9	98
260	Highly sensitive detection of EGFR T790M mutation using colony hybridization predicts favorable prognosis of patients with lung cancer harboring activating EGFR mutation. *Journal of Thoracic Oncology*, **2012**, 7, 1640-4	8.9	94
259	Immunohistochemical detection of EGFR mutation using mutation-specific antibodies in lung cancer. *Clinical Cancer Research*, **2010**, 16, 3349-55	12.9	91
258	Clinicoradiologic characteristics of patients with lung adenocarcinoma harboring EML4-ALK fusion oncogene. *Lung Cancer*, **2012**, 77, 319-25	5.9	89
257	Surgical treatment of lung cancer in the octogenarian. *Annals of Thoracic Surgery*, **1994**, 57, 188-92; discussion 192-3	2.7	88
256	Impact of EGFR mutation analysis in non-small cell lung cancer. *Lung Cancer*, **2009**, 63, 315-21	5.9	84
255	Relationship between early recurrence and micrometastases in the lymph nodes of patients with stage I non-small-cell lung cancer. *Journal of Thoracic and Cardiovascular Surgery*, **1997**, 114, 535-43	1.5	84
254	Micrometastatic tumor cells in the bone marrow of patients with non-small cell lung cancer. *Annals of Thoracic Surgery*, **1997**, 64, 363-7	2.7	82
253	CK20 expression, CDX2 expression, K-ras mutation, and goblet cell morphology in a subset of lung adenocarcinomas. *Journal of Pathology*, **2004**, 203, 645-52	9.4	82

252	Completely resected stage IIIA non-small cell lung cancer: the significance of primary tumor location and N2 station. *Journal of Thoracic and Cardiovascular Surgery*, **2001**, 122, 803-8	1.5	82
251	Risk factors differ for non-small-cell lung cancers with and without EGFR mutation: assessment of smoking and sex by a case-control study in Japanese. *Cancer Science*, **2007**, 98, 96-101	6.9	81
250	Genomic profiling of malignant pleural mesothelioma with array-based comparative genomic hybridization shows frequent non-random chromosomal alteration regions including JUN amplification on 1p32. *Cancer Science*, **2007**, 98, 438-46	6.9	80
249	A phase 3 study of induction treatment with concurrent chemoradiotherapy versus chemotherapy before surgery in patients with pathologically confirmed N2 stage IIIA nonsmall cell lung cancer (WJTOG9903). *Cancer*, **2012**, 118, 6126-35	6.4	78
248	Osimertinib in patients with T790M mutation-positive, advanced non-small cell lung cancer: Long-term follow-up from a pooled analysis of 2 phase 2 studies. *Cancer*, **2019**, 125, 892-901	6.4	78
247	IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy. *Journal of Thoracic Oncology*, **2020**, 15, 709-740	8.9	77
246	Surgery for NSCLC in the era of personalized medicine. *Nature Reviews Clinical Oncology*, **2013**, 10, 235-44	19.4	75
245	Overall survival and local recurrence of 406 completely resected stage IIIa-N2 non-small cell lung cancer patients: questionnaire survey of the Japan Clinical Oncology Group to plan for clinical trials. *Lung Cancer*, **2001**, 34, 29-36	5.9	75
244	Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer. *Molecular Cancer Therapeutics*, **2012**, 11, 2149-57	6.1	73
243	Significance of the Number of Positive Lymph Nodes in Resected Non-small Cell Lung Cancer. *Journal of Thoracic Oncology*, **2006**, 1, 120-125	8.9	73
242	The impact of sex and smoking status on the mutational spectrum of epidermal growth factor receptor gene in non small cell lung cancer. *Clinical Cancer Research*, **2007**, 13, 5763-8	12.9	71
241	CRIPTO1 expression in EGFR-mutant NSCLC elicits intrinsic EGFR-inhibitor resistance. *Journal of Clinical Investigation*, **2014**, 124, 3003-15	15.9	70
240	Effect of selective lymph node dissection based on patterns of lobe-specific lymph node metastases on patient outcome in patients with resectable non-small cell lung cancer: a large-scale retrospective cohort study applying a propensity score. *Journal of Thoracic and Cardiovascular Surgery*, **2010**, 139, 1001-6	1.5	68
239	EGFR mutations in patients with brain metastases from lung cancer: association with the efficacy of gefitinib. *Neuro-Oncology*, **2006**, 8, 137-44	1	68
238	Inflammatory pseudotumor of the lung in adults: radiographic and clinicopathological analysis. *Annals of Thoracic Surgery*, **1989**, 48, 90-5	2.7	68
237	Lung cancer in never smokers: change of a mindset in the molecular era. *Lung Cancer*, **2011**, 72, 9-15	5.9	65
236	A phase II trial evaluating the efficacy and safety of perioperative pirfenidone for prevention of acute exacerbation of idiopathic pulmonary fibrosis in lung cancer patients undergoing pulmonary resection: West Japan Oncology Group 6711L (PEOPLE Study). *Respiratory Research*, **2016**, 17, 90	7.3	65
235	Small cell lung cancer transformation and T790M mutation: complimentary roles in acquired resistance to kinase inhibitors in lung cancer. *Scientific Reports*, **2015**, 5, 14447	4.9	63

234	A 25-signal proteomic signature and outcome for patients with resected non-small-cell lung cancer. *Journal of the National Cancer Institute*, **2007**, 99, 858-67	9.7	63
233	A limited association of OGG1 Ser326Cys polymorphism for adenocarcinoma of the lung. *Journal of Epidemiology*, **2002**, 12, 258-65	3.4	63
232	HNF4□s a marker for invasive mucinous adenocarcinoma of the lung. *American Journal of Surgical Pathology*, **2013**, 37, 211-8	6.7	62
231	PTEN and PIK3CA Expression Is Associated with Prolonged Survival after Gefitinib Treatment in EGFR-Mutated Lung Cancer Patients. *Journal of Thoracic Oncology*, **2006**, 1, 629-634	8.9	62
230	The sensitivity of lung cancer cell lines to the EGFR-selective tyrosine kinase inhibitor ZD1839 (Iressa) is not related to the expression of EGFR or HER-2 or to K-ras gene status. *Lung Cancer*, **2003**, 42, 35-41	5.9	62
229	Management of ground-glass opacities: should all pulmonary lesions with ground-glass opacity be surgically resected?. *Translational Lung Cancer Research*, **2013**, 2, 354-63	4.4	62
228	Impact of one-carbon metabolism-related gene polymorphisms on risk of lung cancer in Japan: a case control study. *Carcinogenesis*, **2007**, 28, 1718-25	4.6	61
227	Sensitivities to various epidermal growth factor receptor-tyrosine kinase inhibitors of uncommon epidermal growth factor receptor mutations L861Q and S768I: What is the optimal epidermal growth factor receptor-tyrosine kinase inhibitor?. *Cancer Science*, **2016**, 107, 1134-40	6.9	61
226	Epidermal growth factor receptor mutations in lung cancers. *Pathology International*, **2007**, 57, 233-44	1.8	60
225	Prospective validation for prediction of gefitinib sensitivity by epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer. *Journal of Thoracic Oncology*, **2007**, 2, 22-8	8.9	60
224	A Screening Method for the ALK Fusion Gene in NSCLC. *Frontiers in Oncology*, **2012**, 2, 24	5.3	59
223	Mutations of epidermal growth factor receptor and K-ras genes in adenosquamous carcinoma of the lung. *International Journal of Cancer*, **2006**, 118, 1588-90	7.5	59
222	Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer.. *New England Journal of Medicine*, **2022**,	59.2	59
221	The association between baseline clinical-radiological characteristics and growth of pulmonary nodules with ground-glass opacity. *Lung Cancer*, **2014**, 83, 61-6	5.9	58
220	How long should small lung lesions of ground-glass opacity be followed?. *Journal of Thoracic Oncology*, **2013**, 8, 309-14	8.9	58
219	Advances in target therapy for lung cancer. *Japanese Journal of Clinical Oncology*, **2010**, 40, 101-6	2.8	58
218	Increased prevalence of EGFR-mutant lung cancer in women and in East Asian populations: analysis of estrogen-related polymorphisms. *Clinical Cancer Research*, **2008**, 14, 4079-84	12.9	57
217	Genetic variants associated with longer telomere length are associated with increased lung cancer risk among never-smoking women in Asia: a report from the female lung cancer consortium in Asia. *International Journal of Cancer*, **2015**, 137, 311-9	7.5	55

216	A clinicopathological study of gastric cancer with special reference to age of the patients: an analysis of 1,630 cases. *World Journal of Surgery*, **1989**, 13, 225-30; discussion 230-1	3.3	54
215	RASSF1A gene inactivation in non-small cell lung cancer and its clinical implication. *International Journal of Cancer*, **2003**, 106, 45-51	7.5	53
214	Molecular epidemiology of lung cancer and geographic variations with special reference to EGFR mutations. *Translational Lung Cancer Research*, **2014**, 3, 205-11	4.4	53
213	PTEN and PIK3CA expression is associated with prolonged survival after gefitinib treatment in EGFR-mutated lung cancer patients. *Journal of Thoracic Oncology*, **2006**, 1, 629-34	8.9	52
212	Sensitivity and Resistance of MET Exon 14 Mutations in Lung Cancer to Eight MET Tyrosine Kinase Inhibitors In Vitro. *Journal of Thoracic Oncology*, **2019**, 14, 1753-1765	8.9	51
211	Molecular oncology of lung cancer. *General Thoracic and Cardiovascular Surgery*, **2011**, 59, 527-37	1.6	51
210	Updated overall survival results of WJTOG 3405, a randomized phase III trial comparing gefitinib (G) with cisplatin plus docetaxel (CD) as the first-line treatment for patients with non-small cell lung cancer harboring mutations of the epidermal growth factor receptor (EGFR).. *Journal of Clinical Oncology*, **2012**, 30, 7521-7521	2.2	51
209	Characterization of EGFR T790M, L792F, and C797S Mutations as Mechanisms of Acquired Resistance to Afatinib in Lung Cancer. *Molecular Cancer Therapeutics*, **2017**, 16, 357-364	6.1	50
208	LKB1 gene mutations in Japanese lung cancer patients. *Cancer Science*, **2007**, 98, 1747-51	6.9	49
207	Maspin expression in normal lung and non-small-cell lung cancers: cellular property-associated expression under the control of promoter DNA methylation. *Oncogene*, **2004**, 23, 4041-9	9.2	48
206	Detection of CYP1A1 gene polymorphism using designed RFLP and distributions of CYP1A1 genotypes in Japanese. *International Archives of Occupational and Environmental Health*, **1995**, 67, 253-6	3.2	48
205	Mutations of the P53 tumor suppressor gene as clonal marker for multiple primary lung cancers. *Journal of Thoracic and Cardiovascular Surgery*, **1997**, 114, 354-60	1.5	47
204	Personalized therapy on the horizon for squamous cell carcinoma of the lung. *Lung Cancer*, **2013**, 80, 249-55	5.9	46
203	Analysis of central nervous system efficacy in the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer. *Lung Cancer*, **2018**, 121, 37-40	5.9	45
202	Conversion from the "oncogene addiction" to "drug addiction" by intensive inhibition of the EGFR and MET in lung cancer with activating EGFR mutation. *Lung Cancer*, **2012**, 76, 292-9	5.9	45
201	EGFR and HER2 genomic gain in recurrent non-small cell lung cancer after surgery: impact on outcome to treatment with gefitinib and association with EGFR and KRAS mutations in a Japanese cohort. *Journal of Thoracic Oncology*, **2009**, 4, 318-25	8.9	45
200	Significance of the Number of Positive Lymph Nodes in Resected Non-small Cell Lung Cancer. *Journal of Thoracic Oncology*, **2006**, 1, 120-125	8.9	45
199	Significant up-regulation of a novel gene, CLCP1, in a highly metastatic lung cancer subline as well as in lung cancers in vivo. *Oncogene*, **2002**, 21, 2822-8	9.2	45

198	A prematurely terminated phase III trial of intraoperative intrapleural hypotonic cisplatin treatment in patients with resected non-small cell lung cancer with positive pleural lavage cytology: the incidence of carcinomatous pleuritis after surgical intervention. *Journal of Thoracic and Cardiovascular Surgery*, **2002**, 123, 695-9	1.5	44
197	Salvage surgery for advanced non-small cell lung cancer after response to gefitinib. *Journal of Thoracic and Cardiovascular Surgery*, **2010**, 140, e69-71	1.5	43
196	Postoperative complications after pneumonectomy for treatment of lung cancer: multivariate analysis. *Journal of Surgical Oncology*, **1996**, 61, 218-22	2.8	43
195	Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer. *Lung Cancer*, **2020**, 139, 195-199	5.9	43
194	hOGG1 Ser326Cys polymorphism and risk of lung cancer by histological type. *Journal of Human Genetics*, **2009**, 54, 739-45	4.3	42
193	Longer survival after resection of non-small cell lung cancer in Japanese women. *Annals of Thoracic Surgery*, **1989**, 48, 639-42	2.7	42
192	The insulin-like growth factor 1 receptor causes acquired resistance to erlotinib in lung cancer cells with the wild-type epidermal growth factor receptor. *International Journal of Cancer*, **2014**, 135, 1002-6	7.5	41
191	Persistent increase in chromosome instability in lung cancer: possible indirect involvement of p53 inactivation. *American Journal of Pathology*, **2001**, 159, 1345-52	5.8	41
190	A single-arm study of sublobar resection for ground-glass opacity dominant peripheral lung cancer. *Journal of Thoracic and Cardiovascular Surgery*, **2020**,	1.5	40
189	Association between GWAS-identified lung adenocarcinoma susceptibility loci and EGFR mutations in never-smoking Asian women, and comparison with findings from Western populations. *Human Molecular Genetics*, **2017**, 26, 454-465	5.6	40
188	Surgical Outcomes of Lung Cancer in Patients with Combined Pulmonary Fibrosis and Emphysema. *Annals of Surgical Oncology*, **2015**, 22 Suppl 3, S1371-9	3.1	39
187	Serum level and tissue expression of c-erbB-2 protein in lung adenocarcinoma. *Chest*, **1995**, 108, 157-62	5.3	38
186	Activity of a novel HER2 inhibitor, poziotinib, for HER2 exon 20 mutations in lung cancer and mechanism of acquired resistance: An in vitro study. *Lung Cancer*, **2018**, 126, 72-79	5.9	38
185	Effect of dasatinib on EMT-mediated-mechanism of resistance against EGFR inhibitors in lung cancer cells. *Lung Cancer*, **2017**, 104, 85-90	5.9	36
184	Identification of a metastasis signature and the DLX4 homeobox protein as a regulator of metastasis by combined transcriptome approach. *Oncogene*, **2007**, 26, 4600-8	9.2	36
183	Expression of human telomerase subunit genes in primary lung cancer and its clinical significance. *Annals of Thoracic Surgery*, **2000**, 70, 401-5; discussion 405-6	2.7	36
182	Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial.. *Lancet, The*, **2022**, 399, 1607-1617	40	35
181	Efficacy and safety of weekly nab-paclitaxel plus carboplatin in patients with advanced non-small cell lung cancer. *Lung Cancer*, **2013**, 81, 97-101	5.9	34

180	Epidermal growth factor receptor mutation, but not sex and smoking, is independently associated with favorable prognosis of gefitinib-treated patients with lung adenocarcinoma. *Cancer Science*, **2008**, 99, 303-8	6.9	34
179	MUC1 mucin mRNA expression in stage I lung adenocarcinoma and its association with early recurrence. *Annals of Thoracic Surgery*, **1999**, 67, 810-4	2.7	34
178	Impact of smoking on lung cancer risk is stronger in those with the homozygous aldehyde dehydrogenase 2 null allele in a Japanese population. *Carcinogenesis*, **2010**, 31, 660-5	4.6	33
177	Association between a genome-wide association study-identified locus and the risk of lung cancer in Japanese population. *Journal of Thoracic Oncology*, **2012**, 7, 790-8	8.9	33
176	Prospective Validation for Prediction of Gefitinib Sensitivity by Epidermal Growth Factor Receptor Gene Mutation in Patients with Non-Small Cell Lung Cancer. *Journal of Thoracic Oncology*, **2007**, 2, 22-28	8.9	33
175	Efficiency of serum copper/zinc ratio for differential diagnosis of patients with and without lung cancer. *Biological Trace Element Research*, **1994**, 42, 115-27	4.5	33
174	Randomized Phase III Study of Pemetrexed Plus Cisplatin Versus Vinorelbine Plus Cisplatin for Completely Resected Stage II to IIIA Nonsquamous Non-Small-Cell Lung Cancer. *Journal of Clinical Oncology*, **2020**, 38, 2187-2196	2.2	32
173	Meta-analysis of genome-wide association studies identifies multiple lung cancer susceptibility loci in never-smoking Asian women. *Human Molecular Genetics*, **2016**, 25, 620-9	5.6	32
172	Impact of age on epidermal growth factor receptor mutation in lung cancer. *Lung Cancer*, **2012**, 78, 207-11	5.9	32
171	Transformation to sarcomatoid carcinoma in ALK-rearranged adenocarcinoma, which developed acquired resistance to crizotinib and received subsequent chemotherapies. *Journal of Thoracic Oncology*, **2013**, 8, e75-8	8.9	32
170	Mutations in the epidermal growth factor receptor gene and effects of EGFR-tyrosine kinase inhibitors on lung cancers. *General Thoracic and Cardiovascular Surgery*, **2008**, 56, 97-103	1.6	32
169	KRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C Inhibitors, Sotorasib and Adagrasib, and Overcoming Strategies: Insights From In Vitro Experiments. *Journal of Thoracic Oncology*, **2021**, 16, 1321-1332	8.9	32
168	Phase II study of erlotinib plus tivantinib (ARQ 197) in patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer just after progression on EGFR-TKI, gefitinib or erlotinib. *ESMO Open*, **2016**, 1, e000063	6	30
167	Heterogeneity in resistance mechanisms causes shorter duration of epidermal growth factor receptor kinase inhibitor treatment in lung cancer. *Lung Cancer*, **2016**, 91, 36-40	5.9	29
166	Interstitial lung disease associated with gefitinib in Japanese patients with EGFR-mutated non-small-cell lung cancer: combined analysis of two Phase III trials (NEJ 002 and WJTOG 3405). *Japanese Journal of Clinical Oncology*, **2013**, 43, 664-8	2.8	29
165	Decreased expression of 14-3-3sigma in neuroendocrine tumors is independent of origin and malignant potential. *Oncogene*, **2002**, 21, 8310-9	9.2	29
164	Oncogene swap as a novel mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor in lung cancer. *Cancer Science*, **2016**, 107, 461-8	6.9	29
163	Outcomes after hepatic and pulmonary metastasectomies compared with pulmonary metastasectomy alone in patients with colorectal cancer metastasis to liver and lungs. *World Journal of Surgery*, **2013**, 37, 1315-21	3.3	28

162	Role of EGFR mutations in lung cancers: prognosis and tumor chemosensitivity. *Archives of Toxicology*, **2015**, 89, 1227-40	5.8	28
161	Hsp90 inhibition overcomes HGF-triggering resistance to EGFR-TKIs in EGFR-mutant lung cancer by decreasing client protein expression and angiogenesis. *Journal of Thoracic Oncology*, **2012**, 7, 1078-85	8.9	28
160	Frequency of MAGE-3 gene expression in HLA-A2 positive patients with non-small cell lung cancer. *Lung Cancer*, **1998**, 20, 117-25	5.9	28
159	MET gene exon 14 deletion created using the CRISPR/Cas9 system enhances cellular growth and sensitivity to a MET inhibitor. *Lung Cancer*, **2015**, 90, 590-7	5.9	26
158	Paravertebral block via the surgical field versus epidural block for patients undergoing thoracotomy: a randomized clinical trial. *Surgery Today*, **2013**, 43, 963-9	3	26
157	Successes and limitations of targeted cancer therapy in lung cancer. *Progress in Tumor Research*, **2014**, 41, 62-77		26
156	The emerging role of epidermal growth factor receptor (EGFR) inhibitors in first-line treatment for patients with advanced non-small cell lung cancer positive for EGFR mutations. *Therapeutic Advances in Medical Oncology*, **2010**, 2, 301-7	5.4	26
155	Clinicopathological features of small-sized non-small cell lung cancer with mediastinal lymph node metastasis. *Lung Cancer*, **2009**, 66, 309-13	5.9	26
154	Soy consumption reduces the risk of non-small-cell lung cancers with epidermal growth factor receptor mutations among Japanese. *Cancer Science*, **2008**, 99, 1202-8	6.9	26
153	FGFR gene alterations in lung squamous cell carcinoma are potential targets for the multikinase inhibitor nintedanib. *Cancer Science*, **2016**, 107, 1667-1676	6.9	26
152	Impact of bevacizumab in combination with erlotinib on EGFR-mutated non-small cell lung cancer xenograft models with T790M mutation or MET amplification. *International Journal of Cancer*, **2016**, 138, 1024-32	7.5	25
151	PTEN and PIK3CA Expression Is Associated with Prolonged Survival after Gefitinib Treatment in EGFR-Mutated Lung Cancer Patients. *Journal of Thoracic Oncology*, **2006**, 1, 629-634	8.9	25
150	Frequent loss of the short arm of chromosome 9 in resected non-small-cell lung cancers from Japanese patients and its association with squamous cell carcinoma. *Journal of Cancer Research and Clinical Oncology*, **1995**, 121, 291-6	4.9	25
149	Kinetic analysis of recurrence and survival after potentially curative resection of nonsmall cell lung cancer. *Journal of Surgical Oncology*, **1996**, 63, 159-65	2.8	25
148	Invasive human fibrosarcoma DNA mediated induction of a 92 kDa gelatinase/type IV collagenase leads to an invasive phenotype. *Biochemical and Biophysical Research Communications*, **1991**, 181, 1539-47	3.4	25
147	EGFR T790M and C797S Mutations as Mechanisms of Acquired Resistance to Dacomitinib. *Journal of Thoracic Oncology*, **2018**, 13, 727-731	8.9	24
146	Overcoming resistance to EGFR tyrosine kinase inhibitors in lung cancer, focusing on non-T790M mechanisms. *Expert Review of Anticancer Therapy*, **2017**, 17, 779-786	3.5	24
145	Relationship of deregulated signaling converging onto mTOR with prognosis and classification of lung adenocarcinoma shown by two independent in silico analyses. *Cancer Research*, **2009**, 69, 4027-35	10.1	24

144	Interferon-gamma differentially regulates susceptibility of lung cancer cells to telomerase-specific cytotoxic T lymphocytes. *International Journal of Cancer*, **2004**, 110, 403-12	7.5	24
143	Topographical distributions of allelic loss in individual non-small-cell lung cancers. *American Journal of Pathology*, **2000**, 157, 985-93	5.8	24
142	Large cell carcinoma of the lung. Prognostic implications of histopathologic and immunohistochemical subtyping. *American Journal of Clinical Pathology*, **1990**, 93, 176-82	1.9	24
141	CD44 Facilitates Epithelial-to-Mesenchymal Transition Phenotypic Change at Acquisition of Resistance to EGFR Kinase Inhibitors in Lung Cancer. *Molecular Cancer Therapeutics*, **2018**, 17, 2257-2265	6.1	23
140	Fluid drainage and air evacuation characteristics of Blake and conventional drains used after pulmonary resection. *Annals of Thoracic Surgery*, **2009**, 87, 1539-45	2.7	23
139	Effects of secondary EGFR mutations on resistance against upfront osimertinib in cells with EGFR-activating mutations in vitro. *Lung Cancer*, **2018**, 126, 149-155	5.9	23
138	Randomized Phase II Study of Adjuvant Chemotherapy with Long-term S-1 versus Cisplatin+S-1 in Completely Resected Stage II-IIIA Non-Small Cell Lung Cancer. *Clinical Cancer Research*, **2015**, 21, 5245-52	12.9	22
137	Feasibility and efficacy of salvage lung resection after definitive chemoradiation therapy for Stage III non-small-cell lung cancer. *Interactive Cardiovascular and Thoracic Surgery*, **2016**, 23, 895-901	1.8	22
136	Patterns of recurrence and outcome in patients with surgically resected small cell lung cancer. *International Journal of Clinical Oncology*, **2012**, 17, 218-24	4.2	22
135	Lung cancers unrelated to smoking: characterized by single oncogene addiction?. *International Journal of Clinical Oncology*, **2011**, 16, 294-305	4.2	22
134	Efficacy of irreversible EGFR-TKIs for the uncommon secondary resistant EGFR mutations L747S, D761Y, and T854A. *BMC Cancer*, **2017**, 17, 281	4.8	21
133	Erlotinib, gefitinib, or chemotherapy for EGFR mutation-positive lung cancer?. *Lancet Oncology, The* , **2011**, 12, 710-1	21.7	21
132	Prognostic evaluation based on a new TNM staging system proposed by the International Association for the Study of Lung Cancer for resected non-small cell lung cancers. *Journal of Thoracic and Cardiovascular Surgery*, **2008**, 136, 1343-8	1.5	21
131	Ground-glass nodules of the lung in never-smokers and smokers: clinical and genetic insights. *Translational Lung Cancer Research*, **2018**, 7, 487-497	4.4	21
130	Brain metastases in oncogene-driven non-small cell lung cancer. *Translational Lung Cancer Research*, **2019**, 8, S298-S307	4.4	20
129	Osimertinib for Japanese patients with T790M-positive advanced non-small-cell lung cancer: A pooled subgroup analysis. *Cancer Science*, **2019**, 110, 2884-2893	6.9	20
128	Therapy-induced E-cadherin downregulation alters expression of programmed death ligand-1 in lung cancer cells. *Lung Cancer*, **2017**, 109, 1-8	5.9	19
127	Primary Double-Strike Therapy for Cancers to Overcome EGFR Kinase Inhibitor Resistance: Proposal from the Bench. *Journal of Thoracic Oncology*, **2017**, 12, 27-35	8.9	19

126	Preoperative evaluation of the depth of chest wall invasion and the extent of combined resections in lung cancer patients. *Lung Cancer*, **2009**, 64, 41-4	5.9	19
125	Throwing new light on lung cancer pathogenesis: updates on three recent topics. *Cancer Science*, **2005**, 96, 63-8	6.9	19
124	Innate Genetic Evolution of Lung Cancers and Spatial Heterogeneity: Analysis of Treatment-Naïve Lesions. *Journal of Thoracic Oncology*, **2018**, 13, 1496-1507	8.9	18
123	Subcategorization of lung cancer based on tumor size and degree of visceral pleural invasion. *Annals of Thoracic Surgery*, **2008**, 86, 1084-90	2.7	18
122	The novel one-step nucleic acid amplification (OSNA) assay for the diagnosis of lymph node metastasis in patients with non-small cell lung cancer (NSCLC): Results of a multicenter prospective study. *Lung Cancer*, **2016**, 97, 1-7	5.9	18
121	Novel metastasis-related gene CIM functions in the regulation of multiple cellular stress-response pathways. *Cancer Research*, **2010**, 70, 9949-58	10.1	17
120	Lung cancer working group report. *Japanese Journal of Clinical Oncology*, **2010**, 40 Suppl 1, i7-12	2.8	17
119	Small peripheral lung adenocarcinoma: clinicopathological features and surgical treatment. *Surgery Today*, **2010**, 40, 191-8	3	17
118	Heterogeneity in Immune Marker Expression after Acquisition of Resistance to EGFR Kinase Inhibitors: Analysis of a Case with Small Cell Lung Cancer Transformation. *Journal of Thoracic Oncology*, **2017**, 12, 1015-1020	8.9	16
117	Pulmonary metastasectomy for gastric cancer: a 13-year single-institution experience. *Surgery Today*, **2013**, 43, 1382-9	3	16
116	Immunohistochemical analysis of phosphorylated epidermal growth factor receptor might provide a surrogate marker of EGFR mutation. *Lung Cancer*, **2009**, 63, 241-6	5.9	16
115	Factors involved in lymph node metastasis in clinical stage I non-small cell lung cancer--from studies of 604 surgical cases. *Lung Cancer*, **2007**, 57, 311-6	5.9	16
114	Clinical Impacts of EGFR Mutation Status: Analysis of 5780 Surgically Resected Lung Cancer Cases. *Annals of Thoracic Surgery*, **2021**, 111, 269-276	2.7	16
113	The Value of Early Depth of Response in Predicting Long-Term Outcome in EGFR-Mutant Lung Cancer. *Journal of Thoracic Oncology*, **2018**, 13, 792-800	8.9	15
112	Validation of a nomogram for predicting overall survival after resection of pulmonary metastases from colorectal cancer at a single center. *World Journal of Surgery*, **2010**, 34, 2973-8	3.3	15
111	Identification of MGB1 as a marker in the differential diagnosis of lung tumors in patients with a history of breast cancer by analysis of publicly available SAGE data. *Journal of Molecular Diagnostics*, **2004**, 6, 90-5	5.1	15
110	MEK inhibitors against MET-amplified non-small cell lung cancer. *International Journal of Oncology*, **2016**, 49, 2236-2244	4.4	14
109	Rapid detection of the epidermal growth factor receptor mutation in non-small-cell lung cancer for analysis of acquired resistance using molecular beacons. *Journal of Molecular Diagnostics*, **2010**, 12, 644-52	5.1	14

108	Subcategorization of resectable non-small cell lung cancer involving neighboring structures. *Annals of Thoracic Surgery*, **2008**, 86, 1076-83; discussion 1083	2.7	14
107	Analysis of beta-tubulin gene alteration in human lung cancer cell lines. *Cancer Letters*, **2003**, 201, 211-6	9.9	14
106	Molecular biological markers and micrometastasis in resected non-small-cell lung cancer. Prognostic implications. *General Thoracic and Cardiovascular Surgery*, **2001**, 49, 545-51		14
105	Usefulness of cumulative smoking dose for identifying the EGFR mutation and patients with non-small-cell lung cancer for gefitinib treatment. *Cancer Science*, **2009**, 100, 1931-4	6.9	13
104	Controversy about small peripheral lung adenocarcinomas: how should we manage them?. *Journal of Thoracic Oncology*, **2007**, 2, 546-52	8.9	13
103	Adjusted Indirect Comparison Using Propensity Score Matching of Osimertinib to Platinum-Based Doublet Chemotherapy in Patients with EGFRm T790M NSCLC Who Have Progressed after EGFR-TKI. *Clinical Drug Investigation*, **2018**, 38, 319-331	3.2	12
102	Stepwise examination for differential diagnosis of primary lung cancer and breast cancer relapse presenting as a solitary pulmonary nodule in patients after mastectomy. *Journal of Surgical Oncology*, **2008**, 98, 510-4	2.8	12
101	Functional Analyses of Mutations in Receptor Tyrosine Kinase Genes in Non-Small Cell Lung Cancer: Double-Edged Sword of DDR2. *Clinical Cancer Research*, **2016**, 22, 3663-71	12.9	11
100	Clinical significance of tumor cavitation in surgically resected early-stage primary lung cancer. *Lung Cancer*, **2017**, 112, 57-61	5.9	11
99	Recent evidence, advances, and current practices in surgical treatment of lung cancer. *Respiratory Investigation*, **2014**, 52, 322-9	3.4	11
98	Knockdown of the epidermal growth factor receptor gene to investigate its therapeutic potential for the treatment of non-small-cell lung cancers. *Clinical Lung Cancer*, **2012**, 13, 488-93	4.9	11
97	Clinical outcomes of advanced non-small cell lung cancer patients screened for epidermal growth factor receptor gene mutations. *Journal of Cancer Research and Clinical Oncology*, **2010**, 136, 527-35	4.9	11
96	Neuroendocrine tumor metastasis to the thyroid gland. *International Journal of Clinical Oncology*, **2007**, 12, 63-7	4.2	11
95	Clinical, Pathological, and Molecular Features of Lung Adenocarcinomas with AXL Expression. *PLoS ONE*, **2016**, 11, e0154186	3.7	11
94	A Randomized Phase II Study Comparing Nivolumab With Carboplatin-Pemetrexed for Patients With EGFR Mutation-Positive Nonsquamous Non-Small-Cell Lung Cancer Who Acquire Resistance to Tyrosine Kinase Inhibitors Not Due to a Secondary T790M Mutation: Rationale and Protocol Design for the WJOG8515L Study. *Clinical Lung Cancer*, **2017**, 18, 719-723	4.9	10
93	RASSF3 downregulation increases malignant phenotypes of non-small cell lung cancer. *Lung Cancer*, **2014**, 83, 23-9	5.9	10
92	CRKL amplification is rare as a mechanism for acquired resistance to kinase inhibitors in lung cancers with epidermal growth factor receptor mutation. *Lung Cancer*, **2014**, 85, 147-51	5.9	10
91	Collateral chemoresistance to anti-microtubule agents in a lung cancer cell line with acquired resistance to erlotinib. *PLoS ONE*, **2015**, 10, e0123901	3.7	10

90	Effect of gefitinib on the survival of patients with recurrence of lung adenocarcinoma after surgery: a retrospective case-matching cohort study. *Surgical Oncology*, **2010**, 19, e144-9	2.5	10
89	Successful management of tracheo-innominate artery fistula using interposition of a thymus pedicle flap. *Journal of Laryngology and Otology*, **1995**, 109, 161-2	1.8	10
88	DNA polymerase-alpha as a putative early relapse marker in non-small cell lung cancer. An immunohistochemical study. *Cancer*, **1991**, 68, 925-9	6.4	10
87	Abortive transformation of temperature-sensitive mutants of rat 3Y1 cells by simian virus 40: effect of cellular arrest states on entry into S phase and cellular proliferation. *Journal of Cellular Physiology*, **1985**, 123, 353-60	7	10
86	Potential effect of spliceosome inhibition in small cell lung cancer irrespective of the MYC status. *PLoS ONE*, **2017**, 12, e0172209	3.7	10
85	Emerging oncogenic fusions other than , , , and in NSCLC and the role of fusions as resistance mechanisms to targeted therapy. *Translational Lung Cancer Research*, **2020**, 9, 2618-2628	4.4	10
84	Lack of association between the BIM deletion polymorphism and the risk of lung cancer with and without EGFR mutations. *Journal of Thoracic Oncology*, **2015**, 10, 59-66	8.9	9
83	Emerging MET tyrosine kinase inhibitors for the treatment of non-small cell lung cancer. *Expert Opinion on Emerging Drugs*, **2020**, 25, 229-249	3.7	9
82	Risk assessment of perioperative mortality after pulmonary resection in patients with primary lung cancer: the 30- or 90-day mortality. *General Thoracic and Cardiovascular Surgery*, **2014**, 62, 308-13	1.6	9
81	Significance of the serum carcinoembryonic antigen level during the follow-up of patients with completely resected non-small-cell lung cancer. *European Journal of Cardio-thoracic Surgery*, **2014**, 45, 687-92	3	9
80	Aspergilloma within cavitating pulmonary carcinoma. Case report. *Scandinavian Journal of Thoracic and Cardiovascular Surgery*, **1993**, 27, 57-60		9
79	Phenotypic characterization of lymphokine-activated killer cells from human lymph node lymphocytes. *Cellular Immunology*, **1989**, 122, 578-84	4.4	9
78	Heterogeneity of EGFR Aberrations and Correlation with Histological Structures: Analyses of Therapy-Naive Isogenic Lung Cancer Lesions with EGFR Mutation. *Journal of Thoracic Oncology*, **2016**, 11, 1711-7	8.9	8
77	Tuberculosis infection and lung adenocarcinoma: Mendelian randomization and pathway analysis of genome-wide association study data from never-smoking Asian women. *Genomics*, **2020**, 112, 1223-1232	4.3	8
76	Solitary pulmonary metastasis from lung cancer harboring EML4-ALK after a 15-year disease-free interval. *Lung Cancer*, **2013**, 80, 99-101	5.9	7
75	Prognostic implication of predominant histologic subtypes of lymph node metastases in surgically resected lung adenocarcinoma. *BioMed Research International*, **2014**, 2014, 645681	3	7
74	Analysis of ERBB4 mutations and expression in japanese patients with lung cancer. *Journal of Thoracic Oncology*, **2010**, 5, 1859-61	8.9	7
73	CT and MRI manifestations of primary pulmonary plasmacytoma. *Clinical Imaging*, **1995**, 19, 17-9	2.7	7

72	Salvage surgery for non-small cell lung cancer after tyrosine kinase inhibitor treatment. *Lung Cancer*, **2021**, 153, 108-116	5.9	7
71	Clinical outcome of node-negative oligometastatic non-small cell lung cancer. *Thoracic Cancer*, **2016**, 7, 670-675	3.2	6
70	Increased EGFR Phosphorylation Correlates with Higher Programmed Death Ligand-1 Expression: Analysis of TKI-Resistant Lung Cancer Cell Lines. *BioMed Research International*, **2017**, 2017, 7694202	3	6
69	Genetic analysis of the catalytic domain of the GAP gene in human lung cancer cell lines. *Human Genetics*, **1994**, 93, 27-31	6.3	6
68	Characteristics of non-small cell lung cancer 3 cm or less in diameter. *Journal of Surgical Oncology*, **1995**, 59, 251-4	2.8	6
67	Abstract 2101A: CNX-2006, a novel irreversible epidermal growth factor receptor (EGFR) inhibitor, selectively inhibits EGFR T790M and fails to induce T790M-mediated resistancein vitro. **2013**,		6
66	Vinorelbine plus cisplatin versus gefitinib in resected non-small cell lung cancer haboring activating EGFR mutation (WJOG6410L).. *Journal of Clinical Oncology*, **2012**, 30, TPS7110-TPS7110	2.2	6
65	Activity of tarloxotinib-E in cells with EGFR exon-20 insertion mutations and mechanisms of acquired resistance. *Thoracic Cancer*, **2021**, 12, 1511-1516	3.2	6
64	Lung Cancer with exon 14 Skipping Mutation: Genetic Feature, Current Treatments, and Future Challenges. *Lung Cancer: Targets and Therapy*, **2021**, 12, 35-50	2.9	6
63	Prognostic impact of pleural lavage cytology in patients with primary lung cancer. *Lung Cancer*, **2016**, 102, 60-64	5.9	5
62	Dacomitinib: another option for EGFR-mutant lung cancer?. *Lancet Oncology, The*, **2014**, 15, 1408-1409	21.7	5
61	Afatinib in lung cancer harboring EGFR mutation in the LUX-Lung trials: six plus three is greater than seven?. *Translational Lung Cancer Research*, **2016**, 5, 446-9	4.4	5
60	Heterogeneity in Tumors and Resistance to EGFR TKI Therapy-Letter. *Cancer Research*, **2016**, 76, 3109-10	10.1	5
59	The effect of gefitinib on B-RAF mutant non-small cell lung cancer and transfectants. *Journal of Thoracic Oncology*, **2007**, 2, 321-4	8.9	4
58	The impact of EGFR mutations on gefitinib sensitivity in non-small cell lung cancer. *Personalized Medicine*, **2004**, 1, 27-34	2.2	4
57	Giant hamartoma of the lung with a high production of carbohydrate antigen 19-9. *Annals of Thoracic Surgery*, **1993**, 55, 511-3	2.7	4
56	p53 Immunostaining Positivity Is Associated With Reduced Survival and Is Imperfectly Correlated With Gene Mutations in Resected Non-small Cell Lung Cancer. *Chest*, **1994**, 106, 377S-381S	5.3	4
55	Randomized Phase III Study of Gefitinib Versus Cisplatin Plus Vinorelbine for Patients With Resected Stage II-IIIA Non-Small-Cell Lung Cancer With Mutation (IMPACT). *Journal of Clinical Oncology*, **2021**, JCO2101729	2.2	4

54	Genetic and Prognostic Differences of Non-small Cell Lung Cancer between Elderly Patients and Younger Counterparts **2012**, 3, 438-43		4
53	Adjuvant therapy of operable nonsmall cell lung cancer: an update. *Current Opinion in Oncology*, **2021**, 33, 47-54	4.2	4
52	Dual blockade of EGFR tyrosine kinase using osimertinib and afatinib eradicates EGFR-mutant Ba/F3 cells. *Oncology Reports*, **2019**, 41, 1059-1066	3.5	4
51	Activity and mechanism of acquired resistance to tarloxotinib in mutant lung cancer: an study. *Translational Lung Cancer Research*, **2021**, 10, 3659-3670	4.4	4
50	Life-threatening complications after pulmonary resection for lung cancer in patients on chronic hemodialysis. *Surgery Today*, **2019**, 49, 513-520	3	3
49	Prognosis and segment-specific nodal spread of primary lung cancer in the right lower lobe. *Thoracic Cancer*, **2015**, 6, 672-7	3.2	3
48	Development of personalized treatments in lung cancer: focusing on the mutations and beyond. *Lung Cancer: Targets and Therapy*, **2013**, 4, 43-53	2.9	3
47	Lymph node metastasis of an esophageal cancer behind the thoracic descending aorta. *Esophagus*, **2010**, 7, 111-114	5.4	3
46	Spatial heterogeneity of acquired resistance mechanisms to 1st/2nd generation EGFR tyrosine kinase inhibitors in lung cancer. *Lung Cancer*, **2020**, 148, 100-104	5.9	3
45	Phase II Study of Neoadjuvant Concurrent Chemo-immuno-radiation Therapy Followed by Surgery and Adjuvant Immunotherapy for Resectable Stage IIIA-B (Discrete N2) Non-small-cell Lung Cancer: SQUAT trial (WJOG 12119L). *Clinical Lung Cancer*, **2021**, 22, 596-600	4.9	3
44	Cell Line Models for Acquired Resistance to First-Line Osimertinib in Lung Cancers-Applications and Limitations. *Cells*, **2021**, 10,	7.9	3
43	Comparison of PD-L1 Expression Status between Pure-Solid Versus Part-Solid Lung Adenocarcinomas. *Biomolecules*, **2019**, 9,	5.9	2
42	Progression after spontaneous regression in lung large cell neuroendocrine carcinoma: Report of a curative resection. *Thoracic Cancer*, **2015**, 6, 655-8	3.2	2
41	Unintentional weakness of cancers: the MEK-ERK pathway as a double-edged sword. *Molecular Cancer Research*, **2013**, 11, 1125-8	6.6	2
40	Papillary carcinoma in a huge intrathoracic goiter with tracheal stenosis and invasion. Case report. *Scandinavian Journal of Thoracic and Cardiovascular Surgery*, **1993**, 27, 165-8		2
39	Integrated clinical and basic studies related to circumventing non-small cell lung cancer drug resistance. *Lung Cancer*, **1994**, 10 Suppl 1, S73-81	5.9	2
38	Osimertinib in Patients with T790M-Positive Advanced Non-small Cell Lung Cancer: Korean Subgroup Analysis from Phase II Studies. *Cancer Research and Treatment*, **2020**, 52, 284-291	5.2	2
37	Dose-dependence in acquisition of drug tolerant phenotype and high RYK expression as a mechanism of osimertinib tolerance in lung cancer. *Lung Cancer*, **2021**, 154, 84-91	5.9	2

36	Drug Tolerance to EGFR Tyrosine Kinase Inhibitors in Lung Cancers with Mutations. *Cells*, **2021**, 10,	7.9	2
35	A phase II study of cisplatin plus vinorelbine combined with atezolizumab as adjuvant therapy for completely resected non-small-cell lung cancer with mutation (West Japan Oncology Group 11719L/ADJUST study). *Therapeutic Advances in Medical Oncology*, **2021**, 13, 1758835920987647	5.4	2
34	Postoperative complications after pneumonectomy for treatment of lung cancer: Multivariate analysis **1996**, 61, 218		2
33	Primary pulmonary mucosa-associated lymphoid tissue lymphoma with amyloid light chain-type amyloidosis. *Surgical Case Reports*, **2019**, 5, 105	0.8	1
32	Comparison of methods for placing and managing a silastic drain after pulmonary resection. *Interactive Cardiovascular and Thoracic Surgery*, **2009**, 9, 645-8	1.8	1
31	M03-01: Molecular predictors of EGFR-TKIs. *Journal of Thoracic Oncology*, **2007**, 2, S156	8.9	1
30	Utility of the Ba/F3 cell system for exploring on-target mechanisms of resistance to targeted therapies for lung cancer.. *Cancer Science*, **2022**,	6.9	1
29	New TNM Classification for Non-small Cell Lung Cancer by Evaluating T Factor Based on Tumor Size and Visceral Pleural Invasion. *Japanese Journal of Lung Cancer*, **2007**, 47, 1-8	0.1	1
28	Comparisons of the New TNM Staging System for Lung Cancer (UICC-7) and Revisions of the General Rules for the Clinical and Pathological Classification of Lung Cancer of the Japan Lung Cancer Society. *Japanese Journal of Lung Cancer*, **2012**, 52, 80-84	0.1	1
27	Adjuvant Chemotherapy in Patients with Completely Resected Lung Cancer: Investigation of the Current Situation After Publication of the Second Edition of Clinical Practice Guidelines for Lung Cancer. *Japanese Journal of Lung Cancer*, **2010**, 50, 280-286	0.1	1
26	Lung Adenocarcinoma Coexistent with Pulmonary Non-tuberculous Mycobacteriosis. *Japanese Journal of Lung Cancer*, **2012**, 52, 238-241	0.1	1
25	Acquired Resistance Mechanism for MET Tyrosine Kinase Inhibitor. *JTO Clinical and Research Reports*, **2021**, 2, 100134	1.4	1
24	Inter- and Intratumor Heterogeneity of EGFR Compound Mutations in Non-Small Cell Lung Cancers: Analysis of Five Cases. *Clinical Lung Cancer*, **2021**, 22, e141-e145	4.9	1
23	Perioperative Therapy for Non-Small Cell Lung Cancer with Immune Checkpoint Inhibitors. *Cancers*, **2021**, 13,	6.6	1
22	EGFR mutations in non-small-cell lung cancer AuthorsPreply. *Lancet Oncology, The*, **2010**, 11, 413	21.7	0
21	Integrin-linked kinase pathway in heterogeneous pulmonary sarcomatoid carcinoma. *Oncology Letters*, **2021**, 21, 320	2.6	0
20	Combined bevacizumab and erlotinib treatment in patients with lung cancer with the T790M resistance mutation. *Lancet Respiratory Medicine,the*, **2017**, 5, 369-370	35.1	
19	Molecular Biology of Lung Cancer. *Japanese Journal of Lung Cancer*, **2010**, 50, 329-341	0.1	

18	The Pharmacogenetic Rescue of Side-Lined Anticancer Drugs to the Front-Line: Gefitinib as a Case Example. *Annals of Pharmacotherapy*, **2011**, 45, 263-75	2.9
17	The close relationship between growth factors and the nucleolar organizer regions in adenocarcinoma of the lung. *European Journal of Surgical Oncology*, **1995**, 21, 398-402	3.6
16	In vitro validation study of HER2 and HER4 mutations identified in an ad hoc secondary analysis of the LUX-Lung 8 randomized clinical trial. *Lung Cancer*, **2021**, 162, 79-85	5.9
15	Mass Screening and Molecular Diagnosis for Lung Cancer. *Japanese Journal of Lung Cancer*, **2005**, 45, 157-165	0.1
14	Mutations in the Epidermal Growth Factor Receptor Gene And Sensitivity to Tyrosine Kinase Inhibitors. *Japanese Journal of Lung Cancer*, **2006**, 46, 237-240	0.1
13	Relationship Between Prognosis and Nodal Micrometastasis in Patients With Non-Small Cell Lung Cancer. *Japanese Journal of Lung Cancer*, **2006**, 46, 23-26	0.1
12	Factors Affecting Postoperative Recurrence in Patients with Pathological Stage IB Non-small-cell Lung Cancer. *Japanese Journal of Lung Cancer*, **2007**, 47, 327-332	0.1
11	The Significance of Changes in Serum CEA Level as a Surrogate Marker for Evaluating Tumor Response to Chemotherapy in Non-small Cell Lung Cancer. *Japanese Journal of Lung Cancer*, **2008**, 48, 26-32	0.1
10	Mediastinal tumors associated with von Recklinghausenβ disease.. *The Journal of the Japanese Association for Chest Surgery*, **1992**, 6, 780-785	0
9	Cavernous lymphangioma extending to the posterior mediastinum and the retroperitoneum; a case report.. *The Journal of the Japanese Association for Chest Surgery*, **1992**, 6, 706-711	0
8	Combined carboplatin and cisplatin therapy in patients with advanced non-small cell lung cancer. *American Journal of Clinical Oncology: Cancer Clinical Trials*, **1997**, 20, 31-5	2.7
7	The History and Current State of EGFR-TKIs. *Japanese Journal of Lung Cancer*, **2017**, 57, 69-74	0.1
6	EGFR Mutation, But Not Sex and Smoking, Is Independently Associated with Favorable Prognosis of Gefitinib-treated Patients with Lung Adenocarcinoma. *Japanese Journal of Lung Cancer*, **2009**, 49, 409-415	0.1
5	EGF receptor-targeted drugs **2011**, 18-37	
4	Abstract IA5: Genetic and genomic difference in lung cancer based on ethnicity. *Clinical Cancer Research*, **2012**, 18, IA5-IA5	12.9
3	Oncogenic driver mutations **2012**, 45-58	
2	Risk Assessment of Perioperative Mortality After Pulmonary Resection for Primary Lung Cancer: the 30-day or 90-day Mortality. *Japanese Journal of Lung Cancer*, **2013**, 53, 93-98	0.1
1	Presence of a Ground-Glass Opacity Component Is the True Prognostic Determinant in Clinical Stage I NSCLC.. *JTO Clinical and Research Reports*, **2022**, 3, 100321	1.4